Fucosylated chondroitin sulfate as a new oral antithrombotic agent

Thrombosis and Haemostasis

Volumn 96, Issue 6, 2006, Pages 822-829

  Fonseca, Roberto J C ^a   Mourão, Paulo A S ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Fucosylated chondroitin sulfate; Glycosaminoglycans; Heparin; Oral anticoagulants

Indexed keywords

ANTICOAGULANT AGENT; CHONDROITIN SULFATE; GLYCOSAMINOGLYCAN; HEPARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTERY THROMBOSIS; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; DRUG ABSORPTION; DRUG STRUCTURE; EXPERIMENTAL MODEL; FEMALE; FUCOSYLATION; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RAT; SEA CUCUMBER; SINGLE DRUG DOSE; STRUCTURE ANALYSIS; THROMBIN TIME; THROMBOGENESIS; VEIN THROMBOSIS;

ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; BLEEDING TIME; BLOOD COAGULATION; CHONDROITIN SULFATES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYTIC AGENTS; HEPARIN; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN; RATS; RATS, WISTAR; SEA CUCUMBERS; THROMBIN TIME; THROMBOSIS; TIME FACTORS;

EID: 33845361767     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-06-0304     Document Type: Article

References (31)

1. Biermann CH, Marks JA, Vilela-Silva AC, et al. Carbohydrate-based species recognition in sea urchin fertilization: another avenue for speciation? Evol Dev 2004; 6: 353-61.
2. Caterson B, Mahmoodian F, Sorrel JM, et al. Modulation ofnative chondroitin sulfate structures in tissue development and disease. J Cell Sci 1990; 97: 411-7.
3. Mourão PAS, Pereira MS. Searching for alternatives to heparin. Trends Cardiovasc Med 1999; 9: 225-32.
4. Mulloy B, Mourão PAS, Gray E. Structure/function studies of anticoagulant sulfated polysaccharides using NMR. J Biotech 2000; 77: 123-35.
5. Mourão PAS, Guimarães B, Mulloy B, et al. Antithrombotic activity of a fucosylated chondroitin sulfate from echinoderm: Sulfated fucose branches on the polysaccharide account for its antithrombotic action. Br J Haematol 1998; 101: 647-52.
6. Pacheco RG, Vicente CP, Zancan P, et al. Different antithrombotic mechanisms among glycosaminoglycans revealed with a new fucosylated chondroitin sulfate from an echinoderm. Blood Coagul Fibrinolysis 2000; 11: 563-73.
7. Zancan P, Mourão PAS. Venous and arterial thrombosis in rat models: dissociation of the antithrombotic effects of glycosaminoglycans. Blood Coagul Fibrinolysis 2004; 15: 45-54.
8. Vieira RP, Mourão PAS. Occurrence of a unique fucose-branched chondroitin sulfate in the body wall of a sea cuccumber. J Biol Chem 1988; 263: 18176-83.
9. Vieira RP, Mulloy B, Mourão PAS. Structure of a fucose-branched chondroitin sulfate from sea cuccumber: evidence for the presence of 3-O-sulfo-β-D-glucuronosyl residues. J Biol Chem 1991; 266: 13530-6.
10. Vinazzer H. Assay of total factor XII and of activated factor XII in plasma with a chromogenic substrate. Thromb Res 1979; 14: 155-166.
11. Wessler S, Reimer SM, Sheps MC. Biological assay of a thrombosis inducing activity in human serum. J Appl Physiol 1959; 14: 943-6.
12. Umetsu T, Sanai K. Effect of 1-methyl-2-mercapto-5-(3-pyridyl)-imidazole (KC-6141), an anti-aggregating compound, on experimental thrombosis in rats. Thromb Haemost 1978; 39: 74-83.
13. Herbert JM, Bernat A, Maffrand JP. Importance of platelets in experimental venous thrombosis in rats. Blood 1992; 80: 2281-6.
14. Mourão PAS, Boisson-Vidal C, Tapon-Bretaudiere J, et al. Inactivation of thrombin by a fucosylated chondroitin sulfate from echinoderm. Thromb Res 2001, 102: 167-76.
15. Zhiguang LI, Hough W, Jiazeng LI, et al. Basic and clinical study on the antithrombotic mechanism of glycosaminoglycan extracted from sea cucumber. Chin Med J 2000; 113: 706-11.
16. Yoon SJ, Pereira MS, Pavão MSG, et al. The medicinal plant Porana volubilis contains polysaccharides with anticoagulant activity mediated by heparin cofactor II. Thromb Res 2002; 106: 51-8.
17. Rocha HAO, Moraes FA, Trindade ES, et al. Structural and hemostatic activities of a sulfated galactofucan from the brown alga Spatoglossum schroederi: an ideal antithrombotic agent? J Biol Chem 2006; 280: 41278-88.
18. Mourão PAS, Pereira MS, Pavão MS. et al. Structure and anticoagulant activity of a facosylated chondroitin sulfate from echinoderm. Sulfated fucose branches on the polysaccharide account for its high anticoagulant action. J Biol Chem 1996; 271: 23973-84.
19. Leadley Jr RJ, Chi L, Rebello SS, et al. Contribution of in vivo models of thrombosis to the discovery and development of novel antithrombotic agents. J Pharmacol Toxicol Methods 2000. 43: 101-16.
20. Hu M, Hsi-Hsien L, Weng-Ching K. Hypolipidemic Effect of glycosaminoglycans from the sea cucumber Metriatyla scabra in rats fed a cholesterol-supplemented diet. J Agric Food Chem 2002; 50: 3602-6.
21. Imanari T, Washio T, Huang H, et al. Oral absorption and clearance of partially depolymerized fucosyl chondroitin sulfate from sea cucumber. Thromb Res 1993: 93: 259-74.
22. Hiebert LM, Pinel C. Wice SM. Orally administered heparins prevent arterial thrombosis in a rat model. Thromb Haemost 2004; 91: 919-26.
23. Hiebert LM, Wice SM, Ping T, et al. Antithrombotic efficacy in a rat model of the low molecular weight heparin, reviparin sodium, administered by the oral route. Thromb Haemost 2001; 85: 114-8.
24. Ronca G, Ronca F, Palmieri L. Anti-inflammatory activity of chondroitin sulfate. Osteoarthrits Cart 1998; 6 (Suppl A): 14-21.
25. Volpi N. Oral bioavailability of chondroitin sulfate (Condrosulf ®) and its constituents in healthy male volunteers. Osteoarthrits Cart 2002; 10: 768-77.
26. Wuisman P. Glucosamine and chondroitin sulfate supplementation to treat symptomatic disc degeneration: Biochemical rationale and case report. BMC Compl Altern Med 2003; 3: 1-8.
27. Houin G, Barthe L, Woodley J, et al. In vitro intestinal degradation and absorption of chondroitin sulfate, a glycosaminoglycan drug. Arzneimittelforschung 2004; 54: 286-92.
28. Gomez-Orellana I, Goldberg M. Challenges for the oral delivery of macromolecules. Nat Rev 2003; 2: 289-95.
29. Hirsh J, Levine LM. Low molecular weight heparin. Blood 1992; 79: 1-18.
30. Perzbone E, Strassburger J, Wilmer A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939: an oral, direct Factor Xa inhibitor. Thromb Haemost 2005; 3: 514-21.
31. Gustafsson D, Bylund R, Antosson T, et al. A new oral anticoagulant: the 50-year challenge. Nat Rev 2004; 3: 649-59.